Group 1 - The company announced that the Phase II clinical trial for BRIMOCHOL™PF, a candidate drug for presbyopia, enrolled its first patient on March 24, 2025 [1] - The Phase II trial is a multicenter, randomized, double-blind, crossover, and placebo-controlled study aimed at evaluating the efficacy and safety of BRIMOCHOL™PF eye drops in Chinese presbyopia patients, involving 14 centers and a total of 119 patients [1] - On March 21, 2025, the company entered into a distribution and supply agreement with Lunatus Marketing & Consulting FZCO for BRIMOCHOL™PF, granting Lunatus exclusive rights to import, distribute, promote, market, and sell the drug in several Middle Eastern countries [1] Group 2 - On April 8, 2025, the company's partner Tenpoint Therapeutics Ltd. announced the submission of a new drug application for BRIMOCHOLPF to the FDA for the treatment of presbyopia [2] - Tenpoint is a global clinical-stage biotechnology company formed from the merger of Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc., focusing on developing breakthrough therapies to restore vision in aging eyes [2]
兆科眼科-B(06622)：BRIMOCHOL™PF第II期临床试验入组首名患者